Imatinib and/or Bosutinib Intolerance
Showing 1 - 25 of >10,000
Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and
Completed
- Leukemia
- No Intervention
-
Cambridge, MassachusettsTakeda
Feb 28, 2023
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission Trial
Recruiting
- Chronic Myeloid Leukemia
- +2 more
- Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
- Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
-
Houston, Texas
- +3 more
Jan 25, 2022
Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)
Not yet recruiting
- Lymphoma, Mantle-Cell
- Zanubrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital
Nov 14, 2023
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Frankfurt (Imatinib, Ponatinib, Blinatumomab)
Recruiting
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Imatinib
- +3 more
-
Frankfurt, GermanyDepartment of Medicine, Hematology and Oncology, Goethe Universi
Sep 24, 2023
Gastrointestinal Stromal Tumors Trial in Seoul (Paclitaxel)
Recruiting
- Gastrointestinal Stromal Tumors
-
Seoul, Korea, Republic ofAsan Medical Center
Dec 30, 2022
Primary Biliary Cholangitis Trial in United States (Seladelpar 10 mg, Placebo)
Recruiting
- Primary Biliary Cholangitis
- Seladelpar 10 mg
- Placebo
-
Chandler, Arizona
- +3 more
Oct 2, 2023
Heart Failure, Type 2 Diabetes, Glucose Intolerance Trial in Montreal (Eplerenone, Spironolactone)
Completed
- Heart Failure
- +2 more
-
Montreal, Quebec, CanadaMontreal Heart Institute
Oct 5, 2022
Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)
Not yet recruiting
- Gastrointestinal Stromal Tumors
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2023
Advanced, Refractory Cancer Trial in Seoul (Imatinib)
Active, not recruiting
- Advanced, Refractory Cancer
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Trial in Worldwide (Imatinib, Nilotinib, Bosutinib)
Recruiting
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Imatinib
- +4 more
-
Longmont, Colorado
- +128 more
Aug 1, 2022
Eosinophilic Myeloid Tumor, Hypereosinophilic Syndrome Trial run by the National Institute of Allergy and Infectious Diseases
Recruiting
- Eosinophilic Myeloid Neoplasm
- Hypereosinophilic Syndrome
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Generalized Anxiety Disorder Trial (Metacognitive Internet delivered Cognitive Behavior Therapy, Intolerance of uncertainty
Not yet recruiting
- Generalized Anxiety Disorder
- Metacognitive Internet delivered Cognitive Behavior Therapy
- Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy
- (no location specified)
Apr 27, 2023
Describe Real World Use of Bosutinib inSingle Centre in Scotland
Completed
- Myeloid Leukemia
-
Glasgow, United Kingdomeatson West of Scotland Cancer Centre
May 3, 2022
Chronic Myeloid Leukemia (CML) Trial in Italy (Ponatinib 15mg QD, Ponatinib 30mg QD)
Not yet recruiting
- Chronic Myeloid Leukemia (CML)
- Ponatinib 15mg QD
- Ponatinib 30mg QD
-
Cagliari, Italy
- +12 more
Jan 31, 2021
ALK+ Anaplastic Large Cell Lymphoma Trial in Wien (Brentuximab vedotin, Imatinib)
Terminated
- ALK+ Anaplastic Large Cell Lymphoma
- Brentuximab vedotin
- Imatinib
-
Wien, AustriaUniversitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abte
Feb 15, 2022
Breast Cancer Trial in United States (gemcitabine HCl, imatinib mesylate)
Terminated
- Breast Cancer
- gemcitabine hydrochloride
- imatinib mesylate
-
Chicago, Illinois
- +8 more
Aug 12, 2022
Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory Trial in Worldwide (Radotinib HCl)
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- +3 more
- Radotinib HCl
-
Uijeongbu-si, Gyeonggi-do, Korea, Republic of
- +17 more
Jan 3, 2022
Recurrent or Metastatic Colorectal Cancer Trial (Nelmastobart and Capecitabine)
Not yet recruiting
- Recurrent or Metastatic Colorectal Cancer
- Nelmastobart and Capecitabine
- (no location specified)
Aug 6, 2023
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in Moscow
Active, not recruiting
- Chronic Myeloid Leukemia
- +2 more
- Imatinib
- +3 more
-
Moscow, Russian FederationNational Research Center for Hematology
Oct 1, 2020
Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera Trial in Houston (Imatinib Mesylate (Gleevec))
Completed
- Chronic Myelomonocytic Leukemia
- +4 more
- Imatinib Mesylate (Gleevec)
-
Houston, TexasUT MD Anderson Cancer Center
Dec 7, 2021
Essential Thrombocythemia Trial (Bomedemstat, Anagrelide, Busulfan)
Not yet recruiting
- Essential Thrombocythemia
- Bomedemstat
- +4 more
- (no location specified)
Oct 6, 2023
Condition Vasoregulation Function Endothelium in CML Getting TKI
Recruiting
- Chronic Myeloid Leukaemia
- taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
-
Moscow, Russian Federation
- +1 more
Jan 11, 2023